Berapakah harga Artiva Biotherapeutics, Inc. (ARTV)

Harga Artiva Biotherapeutics, Inc. (ARTV) adalah $11.09

Apakah topi pasaran Artiva Biotherapeutics, Inc. (ARTV)

Cap pasaran Artiva Biotherapeutics, Inc. (ARTV) adalah $542.19M

Artiva Biotherapeutics, Inc. (ARTV) Hasil Dividen

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Tahun	Hasil Dividen	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Hasil Dividen

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Hasil Dividen	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Syarikat

Hasil Dividen

Negara